<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992832</url>
  </required_header>
  <id_info>
    <org_study_id>DFSC-2018(CR)-08</org_study_id>
    <nct_id>NCT04992832</nct_id>
  </id_info>
  <brief_title>Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）</brief_title>
  <acronym>PRIME-HFrEF</acronym>
  <official_title>Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells for Treatment in Heart Failure Patients With Reduced Ejection Fraction: A Randomized, Double Blind, Placebo-Controlled, Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an exploratory clinical study to observe the safety and efficacy of the&#xD;
      Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in the heart failure patients&#xD;
      with reduced ejection fraction. The study was a 12 months single center, randomized,&#xD;
      double-blind, placebo-controlled trial that included 12 weeks of treatment, and 9 months of&#xD;
      follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a 12-month single center, randomized, double-blind, placebo-controlled trial&#xD;
      that included 12 weeks of treatment, and 9 months of follow-up.We plan to recruit 40&#xD;
      subjects，which were divided into experimental group and control group. The volunteers of the&#xD;
      experimental group will be given peripheral intravenously infusion a dose of 1.0*10^6/kg&#xD;
      human umbilical cord mesenchymal stem cell (HUC-MSC) respectively at 0,6,12 week. The control&#xD;
      group will be given the same dose of 1 percent human serum albumin injection. Then&#xD;
      centralization visit was conducted at 0,7 day, 6,12 week, 6 and 12 month. The primary end&#xD;
      points include cardiac function improvement and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>Day 7, Day 43, Day 91, Day 180, Day 360</time_frame>
    <description>The change in Left ventricular ejection fraction (LVEF) % after the infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 month after treatment</time_frame>
    <description>The comparison of the mortality between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>Day 7, Day 43, Day 91, Day 180, Day 360</time_frame>
    <description>The change in NT-proBNP after the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end diastolic diameter</measure>
    <time_frame>Day 7, Day 43, Day 91, Day 180, Day 360</time_frame>
    <description>The change in Left ventricular end diastolic diameter(LVEDD) after the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walking distance</measure>
    <time_frame>Day 7, Day 43, Day 91, Day 180, Day 360</time_frame>
    <description>The change in 6 minutes walking distance after the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living with Heart Failure Questionnaire（MLHFQ）</measure>
    <time_frame>Day 43, Day 91, Day 180, Day 360</time_frame>
    <description>The change in MLHFQ after the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET/CMR</measure>
    <time_frame>Day 43, Day 180</time_frame>
    <description>The change in PET/CMR after the infusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The volunteers of the experimental group will be given peripheral intravenously a dose of 1.0*10^6/kg human umbilical cord mesenchymal stem cells at 0,6,12 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will be given the same dose of saline containing human albumin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <description>Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>human serum albumin</intervention_name>
    <description>Saline solution containing 1 percent human serum albumin will be infused to the control group.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. LVEF≤40％;&#xD;
&#xD;
          2. NYHA II-IV;&#xD;
&#xD;
          3. Received maximally tolerated guideline-directed medical therapy ( GDMT) for at least 3&#xD;
             months before enrollment;&#xD;
&#xD;
          4. Angiography or coronary CT within 6 months shows that there is no indication for PCI /&#xD;
             CABG; Or PCI / CABG indications, but refused.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe valvular heart disease, congenital heart disease, acute viral myocarditis and&#xD;
             acute coronary syndrome.&#xD;
&#xD;
          2. PCI / CABG, ICD / permanent pacemaker / CRT implantation within 3 months.&#xD;
&#xD;
          3. Recent cerebrovascular disease (&lt;6 months).&#xD;
&#xD;
          4. eGFR&lt;30ml/min, or ALT/AST&gt;120U/L.&#xD;
&#xD;
          5. Hematologic disease: anemia (hemoglobin ≤9.0 g/dL); leukopenia (&lt;3500/μL);&#xD;
             thrombocytopenia (&lt;70000/μL); myeloproliferative disorders, myelodysplastic syndrome,&#xD;
             acute or chronic leukemia, and plasma cell dyscrasias (multiple myeloma, amyloidosis)&#xD;
             .&#xD;
&#xD;
          6. Malignant tumor within 5 years.&#xD;
&#xD;
          7. Life expectancy &lt;1 year according any disease.&#xD;
&#xD;
          8. Uncontrolled acute infectious diseases.&#xD;
&#xD;
          9. Known or suspected of being sensitive to the study drugs or its ingredients.&#xD;
&#xD;
         10. Not suitable for inclusion according to the evaluation of the sponsors or unwilling to&#xD;
             comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongmin Liu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital, Shanghai Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongmin Liu, Doctor</last_name>
    <phone>+86-021-3880451</phone>
    <email>liu.zhongmin@tongji.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Failure Department, East Hospital Affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Han, Pro</last_name>
      <phone>+862138804518</phone>
      <email>dr.hanwei@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Umbilical Cord Mesenchymal Stem Cells</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

